Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance

被引:16
|
作者
Liu, Lin [1 ]
May, Susanne [1 ,2 ]
Richman, Dous D.
Hecht, Frederick M. [3 ]
Markowitz, Martin [4 ]
Daar, Eric S. [5 ]
Routy, Jean-Pierre [6 ]
Margolick, Joseph B. [7 ]
Collier, Ann C. [8 ]
Woelk, Christopher H. [1 ]
Little, Susan J. [1 ]
Smith, Davey M. [1 ,2 ]
机构
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Los Angeles, CA 90095 USA
[6] McGill Univ, McGill Univ Hlth Ctr, Quebec City, PQ, Canada
[7] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[8] George Washington Univ, Washington, DC USA
关键词
algorithms; HIV; prevalence; transmitted drug resistance;
D O I
10.1097/QAD.0b013e3282f5ff71
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: We compared eight genotypic interpretation methods to determine whether the method used would affect the rates of reported transmitted drug resistance. Design: Retrospective cohort study. Methods: For the International AIDS Society-USA method we classified a mutation as resistant if it was a 'major' resistance-associated mutation. For the Stanford algorithm, we classified a mutation as resistant if the score was at least 60 (Stanford 60), and alternatively, if the score was at least 30 (Stanford 30). For Agence Nationale de Recherches sur le SIDA and Rega, we interpreted resistance as either 'intermediate resistance' or 'resistance' (ANRS 1 and Rega 1), and 'resistance' only (ANRS 2 and Rega 2). We also used the calibrated population resistance algorithm. We then determined the rates of transmitted drug resistance within the Acute Infection Early Disease Research Program cohort (n=1311) enrolled between March 1995 and August 2006 using each method; agreement was assessed using kappa coefficients. Results: Differences in estimated rates of transmitted drug resistance using International AIDS Society-USA, calibrated population resistance, Stanford 30, ANRS 1, Rega I and Rega 2 methods were mostly minor for resistance to protease and non-nucleoside reverse transcriptase inhibitors (1% range) and more pronounced for nucleoside reverse transcriptase inhibitors (5% range). For these methods kappa agreement was substantial or almost perfect across all drug classes. The Stanford 60 was most conservative. Conclusions: The persistent high rates of transmitted drug resistance support the need for continued genotypic surveillance. The currently available interpretation algorithms can be used for this purpose. (C) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:835 / 839
页数:5
相关论文
共 50 条
  • [1] Comparison of resistance algorithms to determine prevalence of transmitted drug resistance
    Liu, L.
    May, S.
    Richman, D.
    Pond, S. Kosakovsky
    Frost, S.
    Little, S.
    Smith, D.
    [J]. ANTIVIRAL THERAPY, 2007, 12 (05) : S58 - S58
  • [2] Comparison of resistance algorithms to determine prevalence of transmitted drug resistance
    Liu, L.
    May, S.
    Richman, D.
    Pond, S. Kosakovsky
    Frost, S.
    Little, S.
    Smith, D.
    [J]. ANTIVIRAL THERAPY, 2007, 12 : S58 - S58
  • [3] Prevalence of HIV-1 transmitted drug resistance in Liberia
    Loubet, P.
    Charpentier, C.
    Visseaux, B.
    Nuta, C.
    Adu, E.
    Chapplain, J. M.
    Baysah, M.
    Walters-Doe, S.
    Tattevin, P.
    Peytavin, G.
    Yazdanpanah, Y.
    Descamps, D.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A88 - A88
  • [4] Algorithms for the interpretation of HIV-1 genotypic drug resistance information
    Vercauteren, Jurgen
    Vandamme, Anne-Mieke
    [J]. ANTIVIRAL RESEARCH, 2006, 71 (2-3) : 335 - 342
  • [5] Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002
    Ekachai Jenwitheesuk
    Chotip Watitpun
    Asda Vibhagool
    Wasun Chantratita
    [J]. Annals of Clinical Microbiology and Antimicrobials, 2 (1)
  • [6] Prevalence of HIV-1 transmitted drug resistance in the incarcerated population
    Sapozhnikov, J.
    Young, J. D.
    Patel, M.
    Chiampas, T. D.
    Vaughn, P.
    Badowski, M. E.
    [J]. HIV MEDICINE, 2017, 18 (10) : 756 - 763
  • [7] Community HIV-1 drug resistance is associated with transmitted drug resistance
    Tilghman, M. W.
    Perez-Santiago, J.
    Osorio, G.
    Little, S. J.
    Richman, D. D.
    Mathews, W. C.
    Haubrich, R. H.
    Smith, D. M.
    [J]. HIV MEDICINE, 2014, 15 (06) : 339 - 346
  • [8] The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance
    Gifford, Robert J.
    Liu, Tommy F.
    Rhee, Soo-Yon
    Kiuchi, Mark
    Hue, Stephane
    Pillay, Deenan
    Shafer, Robert W.
    [J]. BIOINFORMATICS, 2009, 25 (09) : 1197 - 1198
  • [9] Short Communication: Prevalence of HIV-1 Transmitted Drug Resistance in Liberia
    Loubet, Paul
    Charpentier, Charlotte
    Visseaux, Benoit
    Nuta, Cecilia
    Adu, Eric
    Chapplain, Jean-Marc
    Baysah, Maima
    Walters-Doe, Sylvia
    Tattevin, Pierre
    Peytavin, Gilles
    Yazdanpanah, Yazdan
    Descamps, Diane
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (09) : 863 - 866
  • [10] Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection
    Booth, Clare L.
    Geretti, Anna Maria
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (06) : 1047 - 1056